Gene · 994
Papers2,079
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
361 to 380 of 2,079
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| A Transient Metabolic State in Melanoma Persister Cells Mediated by Chemotherapeutic Treatments. | Front Mol Biosci | 2021 | 35155562 | PubTator, text mining | PubMed |
| The DNA damage repair-related gene PKMYT1 is a potential biomarker in various malignancies. | Transl Lung Cancer Res | 2021 | 35070764 | PubTator, text mining | PubMed |
| miR-210 Regulates Apoptotic Cell Death during Cellular Hypoxia and Reoxygenation in a Diametrically Opposite Manner. | Biomedicines | 2021 | 35052722 | PubTator, text mining | PubMed |
| Potential biomarkers and signaling pathways associated with the pathogenesis of primary salivary gland carcinoma: a bioinformatics study. | Genomics Inform | 2021 | 35012286 | PubTator, text mining | PubMed |
| Targeting Farnesoid X receptor (FXR) for developing novel therapeutics against cancer. | Mol Biomed | 2021 | 35006466 | PubTator, text mining | PubMed |
| Copy Number Alterations in Hepatoblastoma: Literature Review and a Brazilian Cohort Analysis Highlight New Biological Pathways. | Front Oncol | 2021 | 34956867 | PubTator, text mining | PubMed |
| Withaferin A: From Ancient Remedy to Potential Drug Candidate. | Molecules | 2021 | 34946778 | PubTator, text mining | PubMed |
| Transcription Regulation and Genome Rewiring Governing Sensitivity and Resistance to FOXM1 Inhibition in Breast Cancer. | Cancers (Basel) | 2021 | 34944900 | PubTator, text mining | PubMed |
| The Hippo Signaling Pathway in Cancer: A Cell Cycle Perspective. | Cancers (Basel) | 2021 | 34944834 | PubTator, text mining | PubMed |
| Transcriptomics of single dose and repeated carbon black and ozone inhalation co-exposure highlight progressive pulmonary mitochondrial dysfunction. | Part Fibre Toxicol | 2021 | 34911549 | PubTator, text mining | PubMed |
| Artemisinin Mediates Its Tumor-Suppressive Activity in Hepatocellular Carcinoma Through Targeted Inhibition of FoxM1. | Front Oncol | 2021 | 34900697 | PubTator, text mining | PubMed |
| Gains from no real PAINS: Where 'Fair Trial Strategy' stands in the development of multi-target ligands. | Acta Pharm Sin B | 2021 | 34900527 | PubTator, text mining | PubMed |
| Crosstalk between Plk1, p53, cell cycle, and G2/M DNA damage checkpoint regulation in cancer: computational modeling and analysis. | NPJ Syst Biol Appl | 2021 | 34887439 | PubTator, text mining | PubMed |
| NTRK1/TrkA Activation Overrides the G2/M-Checkpoint upon Irradiation. | Cancers (Basel) | 2021 | 34885133 | PubTator, text mining | PubMed |
| FDI-6 inhibits the expression and function of FOXM1 to sensitize BRCA-proficient triple-negative breast cancer cells to Olaparib by regulating cell cycle progression and DNA damage repair. | Cell Death Dis | 2021 | 34880209 | PubTator, text mining | PubMed |
| High Expression of IKZF2 in Malignant T Cells Promotes Disease Progression in Cutaneous T Cell Lymphoma. | Acta Derm Venereol | 2021 | 34853863 | PubTator, text mining | PubMed |
| Hsa_circ_0030586 promotes epithelial-mesenchymal transition in prostate cancer via PI3K-AKT signaling. | Bioengineered | 2021 | 34852706 | PubTator, text mining | PubMed |
| Novel Ferroptosis-Related Multigene Prognostic Models for Patients with Bladder Cancer. | Int J Gen Med | 2021 | 34849009 | PubTator, text mining | PubMed |
| Single-Cell Transcriptomics Reveals the Expression of Aging- and Senescence-Associated Genes in Distinct Cancer Cell Populations. | Cells | 2021 | 34831349 | PubTator, text mining | PubMed |
| Circular RNAs in prostate cancer: Biogenesis,biological functions, and clinical significance. | Mol Ther Nucleic Acids | 2021 | 34820150 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/994/papers?page=19